目的：观察玻璃体腔注射康柏西普治疗渗出性年龄相关性黄斑变性(age-related macular degeneration，ARMD)的临床疗效。

方法：回顾性研究我院2015-07/2016-01确诊的渗出性ARMD患者45例45眼，采取每月1次玻璃体腔注射康柏西普(0.5mg/0.05mL)，连续治疗3mo，之后按需给药(3+PRN)，随访2a。分别观察治疗前和治疗后最佳矫正视力(best corrected visual acuity，BCVA)、黄斑中心凹厚度(central macular thickness，CMT)变化情况。

结果：治疗后第1、2、3mo，1、2a后的BCVA较治疗前显著提高，差异有统计学意义(t=5.208、5.111、4.323、4.701、5.156，P<0.05)，CMT较治疗前显著减低，差异有统计学意义(t=3.807、4.556、2.841、2.707、3.145，P<0.05)。

结论：康柏西普眼用注射液3+PRN方案治疗渗出性ARMD可以有效提高视力、减轻黄斑水肿。

METHODS: Forty-five patients(45 eyes)with exudative age-related macular degeneration diagnosed in our hospital from July 2015 to January 2016 were retrospectively studied. A monthly intravitreal injection of conbercep was carried out. After 3-month injection, conbercep was given if necessary(3+PRN), and all patients were followed up for 2a. Before and after treatment, the intraocular pressure, the best corrected visual acuity(BCVA), central macular thickness(CMT)changes were observed.

RESULTS: The BCVA at 1, 2, 3mo, 1 and 2a after treatment was better than that before treatment(t=5.208, 5.111, 4. 323, 4.701, 5.156; P<0.05). CMT was significantly lower than before treatment(t=3.807, 4.556, 2.841, 2.707, 3.145; P<0.05).

CONCLUSION: Conbercept injection, as 3+PRN, can effectively improve visual acuity, reduce macular edema.